In situ kinase profiling reveals functionally relevant properties of native kinases

Chemistry and Biology

Volumn 18, Issue 6, 2011, Pages 699-710

  Patricelli, Matthew P ^a   Nomanbhoy, Tyzoon K ^a   Wu, Jiangyue ^a   Brown, Heidi ^a   Zhou, David ^a   Zhang, Jianming ^b   Jagannathan, Subadhra ^a   Aban, Arwin ^a   Okerberg, Eric ^a   Herring, Chris ^a   Nordin, Brian ^a   Weissig, Helge ^a   Yang, Qingkai ^c   Lee, Jiing Dwan ^c   Gray, Nathanael S ^b   Kozarich, John W ^a  

^a ACTIVX BIOSCIENCES INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DASATINIB; MAP2K5 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RAF PROTEIN; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; PROTEIN BINDING; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; CELL LINE, TUMOR; HUMANS; MAP KINASE KINASE 5; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIMIDINES; RAF KINASES; RECOMBINANT PROTEINS; THIAZOLES;

EID: 79959493188     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2011.04.011     Document Type: Article

References (43)

1. M. Bantscheff, D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, S. Hobson, T. Mathieson, J. Perrin, M. Raida, and C. Rau Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 25 2007 1035 1044 (Pubitemid 47517638)
2. K.D. Carey, A.J. Garton, M.S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J.D. Haley, N. Gibson, and M.X. Sliwkowski Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib Cancer Res. 66 2006 8163 8171 (Pubitemid 44299184)
3. M.H. Cohen, G. Williams, J.R. Johnson, J. Duan, J. Gobburu, A. Rahman, K. Benson, J. Leighton, S.K. Kim, and R. Wood Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia Clin. Cancer Res. 8 2002 935 942 (Pubitemid 34520420)
4. P. Cohen Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1 2002 309 315 (Pubitemid 37361447)
5. A. Cuenda, J. Rouse, Y.N. Doza, R. Meier, P. Cohen, T.F. Gallagher, P.R. Young, and J.C. Lee SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1 FEBS Lett. 364 1995 229 233
6. B. Domon, and R. Aebersold Options and considerations when selecting a quantitative proteomics strategy Nat. Biotechnol. 28 2010 710 721
7. A. Donella-Deana, L. Cesaro, M. Ruzzene, A.M. Brunati, O. Marin, and L.A. Pinna Spontaneous autophosphorylation of Lyn tyrosine kinase at both its activation segment and C-terminal tail confers altered substrate specificity Biochemistry 37 1998 1438 1446 (Pubitemid 28135734)
8. C. Garcia-Echeverria, P. Traxler, and D.B. Evans ATP site-directed competitive and irreversible inhibitors of protein kinases Med. Res. Rev. 20 2000 28 57 (Pubitemid 30027560)
9. T.P. Garrington, and G.L. Johnson Organization and regulation of mitogen-activated protein kinase signaling pathways Curr. Opin. Cell Biol. 11 1999 211 218 (Pubitemid 29164036)
10. S.B. Gendreau, R. Ventura, P. Keast, A.D. Laird, F.M. Yakes, W. Zhang, F. Bentzien, B. Cancilla, J. Lutman, and F. Chu Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647 Clin. Cancer Res. 13 2007 3713 3723 (Pubitemid 46955136)
11. K. Godl, J. Wissing, A. Kurtenbach, P. Habenberger, S. Blencke, H. Gutbrod, K. Salassidis, M. Stein-Gerlach, A. Missio, M. Cotten, and H. Daub An efficient proteomics method to identify the cellular targets of protein kinase inhibitors Proc. Natl. Acad. Sci. USA 100 2003 15434 15439 (Pubitemid 38021007)
12. C.A. Hall-Jackson, P.A. Eyers, P. Cohen, M. Goedert, F.T. Boyle, N. Hewitt, H. Plant, and P. Hedge Paradoxical activation of Raf by a novel Raf inhibitor Chem. Biol. 6 1999 559 568 (Pubitemid 29380770)
13. C.A. Hall-Jackson, M. Goedert, P. Hedge, and P. Cohen Effect of SB 203580 on the activity of c-Raf in vitro and in vivo Oncogene 18 1999 2047 2054 (Pubitemid 29178573)
14. O. Hantschel, U. Rix, U. Schmidt, T. Burckstummer, M. Kneidinger, G. Schutze, J. Colinge, K.L. Bennett, W. Ellmeier, P. Valent, and G. Superti-Furga The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib Proc. Natl. Acad. Sci. USA 104 2007 13283 13288 (Pubitemid 47293937)
15. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, R. Alvarado, M.J. Ludlam, D. Stokoe, S.L. Gloor, and G. Vigers RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
16. S.J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, N. Dhomen, J. Hussain, J.S. Reis-Filho, C.J. Springer, C. Pritchard, and R. Marais Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2010 209 221
17. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, and P.T. Edeen A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
18. F.A. Karreth, G.M. DeNicola, S.P. Winter, and D.A. Tuveson C-Raf inhibits MAPK activation and transformation by B-Raf(V600E) Mol. Cell 36 2009 477 486
19. Z.A. Knight, and K.M. Shokat Features of selective kinase inhibitors Chem. Biol. 12 2005 621 637 (Pubitemid 43142039)
20. Y. Kuma, G. Sabio, J. Bain, N. Shpiro, R. Marquez, and A. Cuenda BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo J. Biol. Chem. 280 2005 19472 19479 (Pubitemid 41379467)
21. K.R. Kupcho, R. Bruinsma, T.M. Hallis, D.A. Lasky, R.L. Somberg, T. Turek-Etienne, K.W. Vogel, and K.G. Huwiler Fluroescent cascade and direct assays for characterization of RAF signaling pathway inhibitors Curr. Chem. Genomics 1 2008 43 53
22. K. Lackey, M. Cory, R. Davis, S.V. Frye, P.A. Harris, R.N. Hunter, D.K. Jung, O.B. McDonald, R.W. McNutt, and M.R. Peel The discovery of potent cRaf1 kinase inhibitors Bioorg. Med. Chem. Lett. 10 2000 223 226 (Pubitemid 30105376)
23. D. Leung, C. Hardouin, D.L. Boger, and B.F. Cravatt Discovering potent and selective reversible inhibitors of enzymes in complex proteomes Nat. Biotechnol. 21 2003 687 691 (Pubitemid 36638097)
24. Y. Liu, and N. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2 2006 358 364 (Pubitemid 43936934)
25. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934 (Pubitemid 35425239)
26. E.A. Murphy, D.J. Shields, K. Stoletov, E. Dneprovskaia, M. McElroy, J.I. Greenberg, J. Lindquist, L.M. Acevedo, S. Anand, and B.K. Majeti Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF Proc. Natl. Acad. Sci. USA 107 2010 4299 4304
27. A.C. Newton Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions Chem. Rev. 101 2001 2353 2364 (Pubitemid 35373023)
28. M.E. Noble, J.A. Endicott, and L.N. Johnson Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1805 (Pubitemid 38374863)
29. E.S. Okerberg, J. Wu, B. Zhang, B. Samii, K. Blackford, D.T. Winn, K.R. Shreder, J.J. Burbaum, and M.P. Patricelli High-resolution functional proteomics by active-site peptide profiling Proc. Natl. Acad. Sci. USA 102 2005 4996 5001
30. C. Pargellis, L. Tong, L. Churchill, P.F. Cirillo, T. Gilmore, A.G. Graham, P.M. Grob, E.R. Hickey, N. Moss, S. Pav, and J. Regan Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat. Struct. Biol. 9 2002 268 272 (Pubitemid 34289898)
31. M.P. Patricelli, A.K. Szardenings, M. Liyanage, T.K. Nomanbhoy, M. Wu, H. Weissig, A. Aban, D. Chun, S. Tanner, and J.W. Kozarich Functional interrogation of the kinome using nucleotide acyl phosphates Biochemistry 46 2007 350 358 (Pubitemid 46105428)
32. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
33. J. Regan, C.A. Pargellis, P.F. Cirillo, T. Gilmore, E.R. Hickey, G.W. Peet, A. Proto, A. Swinamer, and N. Moss The kinetics of binding to p38MAP kinase by analogues of BIRB 796 Bioorg. Med. Chem. Lett. 13 2003 3101 3104 (Pubitemid 36993646)
34. H.H. Schiffer, E.C. Reding, S.R. Fuhs, Q. Lu, F. Piu, S. Wong, P.L. Littler, D.M. Weiner, W. Keefe, and P.K. Tan Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer Mol. Pharmacol. 71 2007 508 518 (Pubitemid 46151071)
35. A. Schmidt, M. Claassen, and R. Aebersold Directed mass spectrometry: towards hypothesis-driven proteomics Curr. Opin. Chem. Biol. 13 2009 510 517
36. K. Sharma, C. Weber, M. Bairlein, Z. Greff, G. Kéri, J. Cox, J.V. Olsen, and H. Daub Proteomics strategy for quantitative interaction profiling in cell extracts Nat. Methods 6 2009 741 744
37. K.S. Smalley, and K.T. Flaherty Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment Future Oncol. 5 2009 775 778
38. A.K. Takle, M.J. Brown, S. Davies, D.K. Dean, G. Francis, A. Gaiba, A.W. Hird, F.D. King, P.J. Lovell, and A. Naylor The identification of potent and selective imidazole-based inhibitors of B-Raf kinase Bioorg. Med. Chem. Lett. 16 2006 378 381 (Pubitemid 41680630)
39. L.M. Toledo, N.B. Lydon, and D. Elbaum The structure-based design of ATP-site directed protein kinase inhibitors Curr. Med. Chem. 6 1999 775 805 (Pubitemid 29422195)
40. J. Tsai, J.T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, and N.K. Haass Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. USA 105 2008 3041 3046 (Pubitemid 351723664)
41. C.K. Weber, J.R. Slupsky, H.A. Kalmes, and U.R. Rapp Active Ras induces heterodimerization of cRaf and BRaf Cancer Res. 61 2001 3595 3598 (Pubitemid 32694968)
42. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, and M. McHugh BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 64 2004 7099 7109 (Pubitemid 39331023)
43. J.D. Winkler, H.M. Sarau, J.J. Foley, and S.T. Crooke Phorbol 12-myristate 13-acetate inhibition of leukotriene D4-induced signal transduction was rapidly reversed by staurosporine Biochem. Biophys. Res. Commun. 157 1988 521 529 (Pubitemid 19021211)